Bronte Capital Management’s iShares Biotechnology ETF IBB Stock Holding History

Bronte Capital Management’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$11.7M	Sell	69,265 -3,085	-4%	-$528K	1.16%	23
2025 Q4	$12.2M	Sell	72,350 -209,072	-74%	-$34M	1.22%	19
2025 Q3	$45.4M	Sell	281,422 -13,924	-5%	-$1.9M	4.07%	9
2025 Q2	$42.1M	Buy	295,346 +32,947	+13%	+$4.04M	3.31%	12
2025 Q1	$39.3M	Sell	262,399 -2,187	-0.8%	-$297K	3.19%	12
2024 Q4	$41M	Sell	264,586 -8,369	-3%	-$1.18M	3.24%	11
2024 Q3	$39.7M	Buy	272,955 +512	+0.2%	+$74.1K	3.23%	12
2024 Q2	$37.4M	Sell	272,443 -10,977	-4%	-$1.47M	2.93%	13
2024 Q1	$38.9M	Buy	283,420 +1,892	+0.7%	+$258K	3.17%	11
2023 Q4	$38.2M	Sell	281,528 -1,701	-0.6%	-$208K	3.42%	12
2023 Q3	$34.6M	Sell	283,229 -44,584	-14%	-$5.67M	3.49%	12
2023 Q2	$41.6M	Buy	327,813 +25,737	+9%	+$3.34M	4.01%	7
2023 Q1	$39M	Buy	302,076 +44,461	+17%	+$5.82M	4.53%	8
2022 Q4	$33.8M	Sell	257,615 -5,476	-2%	-$708K	4.27%	10
2022 Q3	$30.8M	Sell	263,091 -21,178	-7%	-$2.63M	3.83%	10
2022 Q2	$33.4M	Buy	+284,269	New	+$33.7M	3.83%	8

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

Commerce Bank Kansas City, Missouri $20.7B AUM 23.76% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Bronte Capital Management's IBB Position: Q1 2026 in Review

Bronte Capital Management reduced its iShares Biotechnology ETF (IBB) stake by 4.3% in Q1 2026, selling an estimated $528K and leaving 69,265 shares worth $11.7M. The position accounts for 1.16% of the portfolio, ranked #23.

Bronte Capital Management first reported a position in IBB in Q2 2022 and has held it in 16 quarters since. The position peaked at $45.4M in Q3 2025. 919 funds tracked by Wall St. Rank hold IBB as of Q1 2026.

Bronte Capital Management held 69,265 shares of iShares Biotechnology ETF worth $11.7M as of Q1 2026.
Bronte Capital Management sold 3,085 iShares Biotechnology ETF shares in Q1 2026, an estimated $528K.
iShares Biotechnology ETF made up 1.16% of Bronte Capital Management's portfolio in Q1 2026, its #23 holding.
Bronte Capital Management first reported a position in iShares Biotechnology ETF in Q2 2022 and has held it in 16 quarters since.
Bronte Capital Management's iShares Biotechnology ETF position peaked at $45.4M in Q3 2025.
919 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q1 2026.

Based on Bronte Capital Management's 13F filing for Q1 2026, filed 27 Apr 2026.